WeTrials
Recruiting

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer

What is this study?

This study is testing a new experimental medicine called MEN2312, both by itself and combined with another medication called elacestrant. Researchers want to see if this approach is safe and helpful for adults with advanced breast cancer.

Who can participate?

You might be able to join if you have advanced breast cancer with specific genetic changes that has grown despite previous treatments like hormone therapy and CDK4/6 inhibitors. However, you cannot join if the cancer has spread to your brain or spinal cord, or if you have severe organ symptoms from the cancer.

What will happen?

Participants will receive the study drug MEN2312, and some may also receive elacestrant. Your health and any side effects will be closely monitored by the study team throughout the process.

Where and when?

This study is currently recruiting participants at locations in Springdale, Arkansas, as well as Duarte and La Jolla, California.

Key Points
  • 1Testing a new experimental drug named MEN2312 for advanced breast cancer
  • 2Open to patients whose cancer has specific genetic changes and progressed on standard treatments
  • 3Currently recruiting patients at select locations in Arkansas and California

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Breast Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.